[Use of bonnecor in the treatment of ventricular arrhythmia].
The effectiveness of the new antiarrhythmic drug bonnecor was tried in 59 patients with ventricular arrhythmia. High antiarrhythmic activity of the drug was recorded in the course doses 150 to 250 mg/day. Bonnecor effect is dose-dependent: the number of ventricular extrasystoles reduced by 75% in 62 and 74% of the patients receiving 150 mg/day and 20 mg/day, respectively. The highest effect was achieved in high-grade ventricular extrasystole. Side effects were occasional: headache lasting 1-2 hours 40-50 min after bonnecor administration, slow atrioventricular conduction (2 cases), sleep disorders (2 cases).
D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003984:Dibenzazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015716:Electrocardiography, Ambulatory; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018879:Ventricular Premature Complexes / Q000175:diagnosis / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; D003984:Dibenzazepines; C048166:tiracizine
Primenenie bonnekora pri lechenii zheludochkovykh aritmiĭ.